From the Sanofi Pasteur Clinical Sciences, Bogotá, Colombia.
Centro de Estudios en Infectología Pediátrica, Cali, Colombia.
Pediatr Infect Dis J. 2018 Nov;37(11):1190-1191. doi: 10.1097/INF.0000000000002172.
This was a safety follow-up study conducted in 382 toddlers in Colombia who had last received dengue vaccine (CYD-TDV) 2 years before. A review of local municipal epidemiologic reports for dengue cases was also conducted for ~28 months postimmunization. One case of clinical dengue was reported; it was neither considered as severe nor related to the study vaccine.
这是一项在哥伦比亚 382 名幼儿中进行的安全性随访研究，他们在 2 年前最后一次接种了登革热疫苗（CYD-TDV）。在免疫接种后约 28 个月，还对当地市级登革热病例的流行病学报告进行了审查。报告了 1 例临床登革热病例；该病例既不被认为是重症病例，也与研究疫苗无关。
